<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970576</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-70/2021</org_study_id>
    <nct_id>NCT04970576</nct_id>
  </id_info>
  <brief_title>Rivaroxaban in Left Ventricular Thrombus</brief_title>
  <official_title>Efficacy of Rivaroxaban in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction: An Open Label Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Cardiovascular Diseases, Karachi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Cardiovascular Diseases, Karachi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The left ventricular (LV) thrombus is an important complication of myocardial infarction (MI)&#xD;
      and vitamin K antagonist (VKA) is the current recommended management therapy for these&#xD;
      patients. However, lack of regular international normalized ratio (INR) monitoring, drug, and&#xD;
      food interaction may leads to increased risk of over or under anticoagulation consequently&#xD;
      compromising the effectiveness of the therapy. Hence, due to benefits like predictable dosing&#xD;
      and lack of need for regular monitoring, use of non-vitamin K antagonist oral anticoagulants&#xD;
      (NOACs) for these patients is increasing among cardiologists. However, clinical data for the&#xD;
      justified use of NOACs in LV thrombus (LVT) are lacking and remained a point of debate among&#xD;
      the cardiologists. A recently published Randomized Control Trial (RCT) by Abdelnabi M et al.&#xD;
      namely the No-LVT trial, had established the safety of Rivaroxaban therapy in patient with&#xD;
      post myocardial infarction (MI) LV thrombus along with promising efficacy. However, sample&#xD;
      size of the study (n=79; 39 in Rivaroxaban and 40 Warfarin) was not sufficiently high enough&#xD;
      to conclude efficacy of Rivaroxaban in these patients. Therefore, this open label RCT is&#xD;
      designed with the primary objective to evaluate the efficacy of Rivaroxaban in resolution of&#xD;
      post MI LV thrombus as compared to standard warfarin therapy at the interval of 1 month and 3&#xD;
      months to test the hypothesis that Rivaroxaban is safe and non-inferior in preventing&#xD;
      thromboembolic and major bleeding events in these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Transthoracic echocardiography assessment for the dissolution of LV thrombus will be blinded to the treatment group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular (LV) thrombus</measure>
    <time_frame>After 12 weeks of randomization</time_frame>
    <description>Presence or absence of LV thrombus on transthoracic echocardiographic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke or systemic embolism</measure>
    <time_frame>Within 12 weeks of randomization</time_frame>
    <description>Confirmed on computerized tomography (CT) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Within 12 weeks of randomization</time_frame>
    <description>As per the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Left Ventricular Thrombus</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the intervention group will receive Rivaroxaban 20 mg once a day (OD) for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the control group will receive usual warfarin therapy dose adjusted as per the target INR of 2 to 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of acute coronary syndrome with LV thrombus&#xD;
&#xD;
          -  Hemodynamically stable&#xD;
&#xD;
          -  Willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of cardiomyopathy&#xD;
&#xD;
          -  Anticoagulant contraindications&#xD;
&#xD;
          -  Prior history of stroke with residual neurological deficit&#xD;
&#xD;
          -  Valvular atrial fibrilation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Mentally retarded&#xD;
&#xD;
          -  Deranged liver function tests (LFTS)&#xD;
&#xD;
          -  Creatinine Clearance &lt;50 ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jehangir A Shah, FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jehangir A Shah, FCPS</last_name>
    <phone>+923332608751</phone>
    <email>dr_shah_80@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Cardiovascular Diseases</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75510</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shumaila Furnaz, MSc</last_name>
      <phone>+92-21-99201271-5</phone>
      <phone_ext>432</phone_ext>
      <email>shumailafurnaz41@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <results_reference>
    <citation>Abdelnabi M, Saleh Y, Fareed A, Nossikof A, Wang L, Morsi M, Eshak N, Abdelkarim O, Badran H, Almaghraby A. Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial). J Am Coll Cardiol. 2021 Mar 30;77(12):1590-1592. doi: 10.1016/j.jacc.2021.01.049.</citation>
    <PMID>33766266</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 10, 2021</last_update_submitted>
  <last_update_submitted_qc>July 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Cardiovascular Diseases, Karachi</investigator_affiliation>
    <investigator_full_name>Jehangir Ali Shah</investigator_full_name>
    <investigator_title>Assistant Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

